Drug Profile
TUTI 16
Alternative Names: Thymon Universal Tat Immunogen; TUTI-16Latest Information Update: 22 Sep 2015
Price :
$50
*
At a glance
- Originator Thymon LLC
- Developer Thymon
- Class AIDS vaccines; Antibodies; Lipopeptides; Vaccines
- Mechanism of Action Human immunodeficiency virus tat gene product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 22 Sep 2015 No recent reports on development identified - Phase-I/II for HIV-1 infections in USA (SC)
- 30 Jun 2012 Thymon LLC completes a phase I/II trial in HIV-1 infections in USA (NCT01335191)
- 11 Jan 2012 Thymon completes enrolment in its phase I/II trial for HIV-1 infections in USA (NCT01335191)